company background image
CYCN

Cyclerion Therapeutics NasdaqCM:CYCN Stock Report

Last Price

US$0.79

Market Cap

US$34.2m

7D

51.4%

1Y

-67.9%

Updated

27 Nov, 2022

Data

Company Financials +
CYCN fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

CYCN Stock Overview

Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases.

Cyclerion Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Cyclerion Therapeutics
Historical stock prices
Current Share PriceUS$0.79
52 Week HighUS$2.50
52 Week LowUS$0.35
Beta1.75
1 Month Change36.52%
3 Month Change-2.85%
1 Year Change-67.88%
3 Year Change-57.47%
5 Year Changen/a
Change since IPO-93.71%

Recent News & Updates

Cyclerion stock tanks 32% on workforce reduction, clinical development refocus

Oct 06

We're Keeping An Eye On Cyclerion Therapeutics' (NASDAQ:CYCN) Cash Burn Rate

Aug 09
We're Keeping An Eye On Cyclerion Therapeutics' (NASDAQ:CYCN) Cash Burn Rate

Recent updates

We're Keeping An Eye On Cyclerion Therapeutics' (NASDAQ:CYCN) Cash Burn Rate

Aug 09
We're Keeping An Eye On Cyclerion Therapeutics' (NASDAQ:CYCN) Cash Burn Rate

We're Keeping An Eye On Cyclerion Therapeutics' (NASDAQ:CYCN) Cash Burn Rate

Mar 03
We're Keeping An Eye On Cyclerion Therapeutics' (NASDAQ:CYCN) Cash Burn Rate

Who Has Been Buying Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Shares?

Mar 09
Who Has Been Buying Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Shares?

What Kind Of Shareholders Hold The Majority In Cyclerion Therapeutics, Inc.'s (NASDAQ:CYCN) Shares?

Jan 28
What Kind Of Shareholders Hold The Majority In Cyclerion Therapeutics, Inc.'s (NASDAQ:CYCN) Shares?

Can You Imagine How Cyclerion Therapeutics' (NASDAQ:CYCN) Shareholders Feel About The 40% Share Price Increase?

Dec 20
Can You Imagine How Cyclerion Therapeutics' (NASDAQ:CYCN) Shareholders Feel About The 40% Share Price Increase?

Shareholder Returns

CYCNUS BiotechsUS Market
7D51.4%0.4%1.3%
1Y-67.9%-14.4%-18.5%

Return vs Industry: CYCN underperformed the US Biotechs industry which returned -14.4% over the past year.

Return vs Market: CYCN underperformed the US Market which returned -18.5% over the past year.

Price Volatility

Is CYCN's price volatile compared to industry and market?
CYCN volatility
CYCN Average Weekly Movement23.0%
Biotechs Industry Average Movement11.1%
Market Average Movement7.4%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market3.3%

Stable Share Price: CYCN is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 23% a week.

Volatility Over Time: CYCN's weekly volatility has increased from 18% to 23% over the past year.

About the Company

FoundedEmployeesCEOWebsite
201832Peter Hechthttps://www.cyclerion.com

Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology; and Phase 1 trials diagnosed with schizophrenia in adults. It is also developing Praliciguat, an orally administered systemic sGC stimulator, which is in Phase II studies to treat resistant hypertension and diabetic nephropathy; Olinciguat, an orally administered vascular sGC stimulator that is in Phase II studies for the sickle cell disease; and CY3018 for the treatment of disorders of the CNS.

Cyclerion Therapeutics, Inc. Fundamentals Summary

How do Cyclerion Therapeutics's earnings and revenue compare to its market cap?
CYCN fundamental statistics
Market CapUS$34.23m
Earnings (TTM)-US$47.64m
Revenue (TTM)US$1.55m

22.1x

P/S Ratio

-0.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CYCN income statement (TTM)
RevenueUS$1.55m
Cost of RevenueUS$33.56m
Gross Profit-US$32.01m
Other ExpensesUS$15.63m
Earnings-US$47.64m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.10
Gross Margin-2,064.90%
Net Profit Margin-3,073.35%
Debt/Equity Ratio0.0%

How did CYCN perform over the long term?

See historical performance and comparison